GlassScriptPhysician profile
Nathaniel Aaron Yokell
NPI 1245855493
$2,976.87
in general payments reported to CMS, 2019-2025
29 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $333 · 2024: $1,563 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,876.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.46 | 2023-2025 | Ubrelvy, Vraylar |
| Pfizer INC. | $399.42 | 2024-2025 | |
| Lilly USA, LLC | $304.58 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $267.19 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $263.97 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.36 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $145.50 | 2023-2025 | Veozah |
| Lundbeck LLC | $86.80 | 2024-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $74.39 | 2024-2025 | Spravato |
| Aimmune Therapeutics, INC. | $66.95 | 2024-2025 | Zenpep |
| Organon LLC | $60.04 | 2023-2024 | Nexplanon |
| Dexcom, INC. | $54.71 | 2024-2025 | Dexcom G6 Transmitter |
| Inogen, INC. | $53.68 | 2024 | |
| Exact Sciences Corporation | $49.40 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.54 | 2024-2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.23 | 2023-2024 | Prolia, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $44.46 | 2024-2025 | Airsupra, Farxiga |
| Corcept Therapeutics | $31.76 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $30.28 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $30.16 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $30.15 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $28.99 | 2025 | |
| Merck Sharp & Dohme LLC | $28.14 | 2023-2024 | Belsomra, Capvaxive, M-M-R II |
| Coopersurgical, INC. | $21.59 | 2025 | Paragard T 380a |
| Viatris Specialty LLC | $20.44 | 2025 | Yupelri |
| Nestle Healthcare Nutrition INC. | $18.51 | 2023 | |
| Abbott Laboratories | $15.83 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $15.26 | 2024 | Keveyis |
| Novartis Pharmaceuticals Corporation | $15.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Yokell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.